Bolt Historical Income Statement

BOLT Stock  USD 0.57  0  0.18%   
Historical analysis of Bolt Biotherapeutics income statement accounts such as Interest Income of 6.5 M, Depreciation And Amortization of 2.5 M or Interest Expense of 1.8 M can show how well Bolt Biotherapeutics performed in making a profits. Evaluating Bolt Biotherapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Bolt Biotherapeutics's future profits or losses.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Bolt Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bolt Biotherapeutics is a good buy for the upcoming year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bolt Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Bolt Stock please use our How to Invest in Bolt Biotherapeutics guide.

About Bolt Income Statement Analysis

Bolt Biotherapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Bolt Biotherapeutics shareholders. The income statement also shows Bolt investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Bolt Biotherapeutics Income Statement Chart

At this time, Bolt Biotherapeutics' Net Interest Income is comparatively stable compared to the past year. Interest Income is likely to gain to about 6.5 M in 2024, whereas Other Operating Expenses is likely to drop slightly above 67.2 M in 2024.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Bolt Biotherapeutics. It is also known as Bolt Biotherapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.
Most accounts from Bolt Biotherapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Bolt Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bolt Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Bolt Stock please use our How to Invest in Bolt Biotherapeutics guide.At this time, Bolt Biotherapeutics' Net Interest Income is comparatively stable compared to the past year. Interest Income is likely to gain to about 6.5 M in 2024, whereas Other Operating Expenses is likely to drop slightly above 67.2 M in 2024.
 2021 2022 2023 2024 (projected)
Interest Income281K2.2M6.2M6.5M
Net Interest Income281K2.2M6.2M6.5M

Bolt Biotherapeutics income statement Correlations

1.00.420.690.61-0.65-0.58-0.630.59-0.640.610.74-0.560.7-0.520.010.81-0.75
1.00.420.690.61-0.65-0.58-0.630.59-0.640.610.74-0.560.7-0.520.010.81-0.75
0.420.420.890.93-0.93-0.94-0.940.94-0.930.930.83-0.95-0.07-0.940.350.66-0.65
0.690.690.890.98-0.97-0.95-0.970.97-0.970.980.99-0.940.24-0.920.230.85-0.83
0.610.610.930.98-0.99-0.99-0.991.0-0.991.00.94-0.990.11-0.970.330.8-0.79
-0.65-0.65-0.93-0.97-0.990.991.0-0.991.0-0.99-0.920.99-0.130.98-0.35-0.820.8
-0.58-0.58-0.94-0.95-0.990.990.99-0.990.99-0.99-0.881.0-0.010.99-0.44-0.750.74
-0.63-0.63-0.94-0.97-0.991.00.99-0.991.0-0.99-0.920.99-0.120.98-0.35-0.810.79
0.590.590.940.971.0-0.99-0.99-0.99-0.991.00.92-0.990.07-0.980.360.78-0.77
-0.64-0.64-0.93-0.97-0.991.00.991.0-0.99-0.99-0.920.99-0.130.98-0.35-0.810.8
0.610.610.930.981.0-0.99-0.99-0.991.0-0.990.94-0.990.11-0.970.330.8-0.79
0.740.740.830.990.94-0.92-0.88-0.920.92-0.920.94-0.880.34-0.850.150.87-0.84
-0.56-0.56-0.95-0.94-0.990.991.00.99-0.990.99-0.99-0.880.01.0-0.45-0.740.73
0.70.7-0.070.240.11-0.13-0.01-0.120.07-0.130.110.340.00.08-0.690.63-0.6
-0.52-0.52-0.94-0.92-0.970.980.990.98-0.980.98-0.97-0.851.00.08-0.52-0.680.67
0.010.010.350.230.33-0.35-0.44-0.350.36-0.350.330.15-0.45-0.69-0.52-0.130.16
0.810.810.660.850.8-0.82-0.75-0.810.78-0.810.80.87-0.740.63-0.68-0.13-0.99
-0.75-0.75-0.65-0.83-0.790.80.740.79-0.770.8-0.79-0.840.73-0.60.670.16-0.99
Click cells to compare fundamentals

Bolt Biotherapeutics Account Relationship Matchups

Bolt Biotherapeutics income statement Accounts

201920202021202220232024 (projected)
Net Interest Income524K199K281K2.2M6.2M6.5M
Interest Income524K199K281K2.2M6.2M6.5M
Depreciation And Amortization377K2.5M3.7M4.9M1.9M2.5M
Selling General Administrative5.2M9.1M18.4M22.9M22.5M14.7M
Total Revenue215K231K1.3M5.7M7.9M8.3M
Other Operating Expenses31.2M49.4M94.0M96.1M84.1M67.2M
Operating Income(31.0M)(49.2M)(92.8M)(90.3M)(76.2M)(80.0M)
Net Income From Continuing Ops(30.5M)(60.7M)(98.6M)(88.1M)(71.3M)(74.9M)
Ebit(31.0M)(51.1M)(95.3M)(93.5M)(76.2M)(80.0M)
Research Development26.0M40.4M75.7M73.1M61.5M52.5M
Ebitda(30.6M)(48.6M)(91.6M)(88.7M)(74.3M)(78.1M)
Total Operating Expenses31.2M49.4M94.0M96.1M84.1M67.2M
Reconciled Depreciation335K611K1.2M1.7M1.8M1.1M
Income Before Tax(30.5M)(60.7M)(98.6M)(88.1M)(69.2M)(72.7M)
Total Other Income Expense Net482K(11.5M)(5.8M)2.2M7.0M7.3M
Net Income Applicable To Common Shares(30.5M)(60.7M)(98.6M)(88.1M)(79.3M)(83.3M)
Net Income(30.0M)(72.3M)(104.4M)(85.9M)(69.2M)(72.7M)
Income Tax Expense(482K)11.5M5.8M(2.2M)1.7M2.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Bolt Stock Analysis

When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.